"Diphenylamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In humans it may be irritating to mucous membranes. Methemoglobinemia has been produced experimentally. In veterinary use, it is one of active ingredients in topical agents for prevention and treatment of screwworm infestation. An indicator in tests for nitrate poisoning.
| Descriptor ID |
D004159
|
| MeSH Number(s) |
D02.092.146.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Diphenylamine".
Below are MeSH descriptors whose meaning is more specific than "Diphenylamine".
This graph shows the total number of publications written about "Diphenylamine" by people in this website by year, and whether "Diphenylamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diphenylamine" by people in Profiles.
-
Schwartz AD, Barney LE, Jansen LE, Nguyen TV, Hall CL, Meyer AS, Peyton SR. A biomaterial screening approach reveals microenvironmental mechanisms of drug resistance. Integr Biol (Camb). 2017 Dec 11; 9(12):912-924.
-
Roy J, Kim B, Hill E, Visconti P, Krapf D, Vinegoni C, Weissleder R, Brown D, Breton S. Tyrosine kinase-mediated axial motility of basal cells revealed by intravital imaging. Nat Commun. 2016 Feb 12; 7:10666.
-
Gratz IK, Rosenblum MD, Maurano MM, Paw JS, Truong HA, Marshak-Rothstein A, Abbas AK. Cutting edge: Self-antigen controls the balance between effector and regulatory T cells in peripheral tissues. J Immunol. 2014 Feb 15; 192(4):1351-5.
-
Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Ma WW, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh LT, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 01; 19(5):1232-43.